Silence Therapeutics Plc American Depository Share (SLN)
SLN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$8.87
-8.08% on the day
Market cap
$551.3M
Small cap
Revenue · 2025
$559K
-98.7% on 2024
Net income · 2025
-$88.6M
-15851.5% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | SLN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United Kingdom |
| IPO year | Not reported by the screener |
| SEC CIK | 0001479615 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | X0 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $559K |
| Net income | -$88.6M |
| Operating income | -$91.1M |
| Net margin | -15851.5% |
| Operating margin | -16292.8% |
| Revenue growth | -98.7% |
| Cash | $11.3M |
| Total assets | $131.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 986.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-08-12 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-08-10 |
| Latest current report | 8-K | 2026-08-12 |
| Latest proxy | DEF 14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 271 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -7.7% |
| 1 month | -27.3% |
| 3 months | -17.0% |
| Year to date | +49.0% |
| 1 year | +64.7% |
| From 52-week high | -41.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| STTK | Shattuck Labs Inc. | $5.49 | -9.85% | $551.0M |
| FTH | Faeth Therapeutics Inc. | $21.51 | -7.48% | $555.8M |
| SGMT | Sagimet Biosciences Inc. Series A | $7.98 | -9.32% | $562.9M |
| PHAT | Phathom Pharmaceuticals Inc. | $7.00 | -1.82% | $566.3M |
| CRMD | CorMedix Inc. | $7.39 | -0.94% | $576.0M |
| PBYI | Puma Biotechnology Inc | $10.12 | -1.65% | $522.4M |
| AQST | Aquestive Therapeutics Inc. | $4.67 | -2.91% | $586.1M |
| NVCT | Nuvectis Pharma Inc. | $18.15 | -7.82% | $591.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier